Medline (NASDAQ:MDLN) Coverage Initiated by Analysts at JPMorgan Chase & Co.

Equities research analysts at JPMorgan Chase & Co. began coverage on shares of Medline (NASDAQ:MDLN) in a report issued on Monday,Benzinga reports. The brokerage set an “overweight” rating and a $50.00 price target on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 23.40% from the stock’s current price.

MDLN has been the subject of a number of other research reports. Mizuho initiated coverage on shares of Medline in a research note on Monday. They set an “outperform” rating and a $48.00 price target for the company. Evercore ISI began coverage on Medline in a research report on Monday. They set an “outperform” rating and a $50.00 target price for the company. Wall Street Zen upgraded Medline to a “hold” rating in a research report on Saturday. UBS Group initiated coverage on Medline in a report on Monday. They set a “buy” rating and a $48.00 price objective for the company. Finally, TD Cowen initiated coverage on Medline in a report on Monday. They set a “buy” rating and a $46.00 price target for the company. Eighteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.25.

Medline Price Performance

Shares of MDLN stock opened at $40.52 on Monday. Medline has a 52-week low of $34.89 and a 52-week high of $45.50.

Insiders Place Their Bets

In other news, Director Charles N. Mills bought 2,579,310 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average cost of $29.00 per share, for a total transaction of $74,799,990.00. Following the completion of the acquisition, the director owned 2,441,379 shares in the company, valued at approximately $70,799,991. This represents a -1,870.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the company’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the sale, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. This trade represents a 55.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.